AI-generated summary
The authors report a pragmatic double-blind randomized trial comparing vascular photobiomodulation with simulated treatment in post-COVID-19 patients with persistent tension-type headache or orofacial pain. They found significant between-group differences in average pain and several pain-interference measures, but no significant difference in headache impact on daily activities. The abstract reports these findings without describing the sample size or wavelengths used.
- Who or what was studied
- Post-COVID-19 patients with tension-type headache, orofacial pain, or both persisting for more than 3 months
- Limits stated in the abstract
- The abstract does not report the sample size or the specific wavelengths used, and the headache impact measure showed no significant difference.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on nature.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Visual analogue scale. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.